EP0776217A1 - Methode de traitement d'un patient a l'aide d'un compose biologiquement actif - Google Patents

Methode de traitement d'un patient a l'aide d'un compose biologiquement actif

Info

Publication number
EP0776217A1
EP0776217A1 EP95927660A EP95927660A EP0776217A1 EP 0776217 A1 EP0776217 A1 EP 0776217A1 EP 95927660 A EP95927660 A EP 95927660A EP 95927660 A EP95927660 A EP 95927660A EP 0776217 A1 EP0776217 A1 EP 0776217A1
Authority
EP
European Patent Office
Prior art keywords
factor viii
immunoglobulin
formulation
kit
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95927660A
Other languages
German (de)
English (en)
Inventor
Lisbeth Tofte Hemmingsen
Per Karsgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0776217A1 publication Critical patent/EP0776217A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Definitions

  • the present invention relates to a method for treating a patient with an immunoglobulin formulation to prevent development of antibodies against Factor VIII in patients suffering from haemophilia A, and the use of an immunoglobulin formulation for the preparation of a pharmaceutical preparation for preventing inhibitor formation in patients suffering from haemophilia A when instituting treatment with Factor VIII.
  • Haemophilia A is an X-chromosome-linked inherited disease which afflicts 1-2 males per 10,000. The disease is caused by an absence of deficiency of Factor VIII:C.
  • Factor VIII.C is a very large glycoprotein (native M r 330 K - 360 K), which is present in plasma at extremely low concentrations. It is a necessary element in the proteolytic cascade which converts soluble fibrinogen to insoluble fibrin, forming a clot to prevent blood loss from traumatized tissue. In the bloodstream, it is found in noncovalent association with von Willebrand factor (vWF) which acts as a stabilizing carrier protein.
  • vWF von Willebrand factor
  • Factor VIII:C is very susceptible to cleavage by thrombin, Factor Xa, protein C, and other serine proteases. It is generally isolated from plasma or plasma products as a series of related polypeptides ranging from M r 160 K-40 K with predominant species of M j . 92 K and M r 80 K-77 K. This complex pattern has made the analysis of the structure of active Factor VIII:C very difficult.
  • the conventional treatment of haemophilia A is replacement therapy comprising administration of Factor VIII (antihaemophilic factor, or "AHF"). Such administration may be therapeutic to control an acute bleeding episode or prophylactic to prevent bleeding episodes in order to allow the patient to normalize his life.
  • AHF antihaemophilic factor
  • the Factor VIII administered to haemophiliacs may be purified in various ways from the plasma of donors or produced by recombinant DNA techniques.
  • Inhibitors are antibodies against Factor VIII :C which develop in response to the Factor VIII treatment of previously untreated patients (PUPs). The antibodies specifically neutralize the Factor VIII procoagulant activity.
  • Lusher et al New England Journal of Medicine, Vol 328, No.7, pp 453-458, February 18,1993 discloses that treatment of PUPs with haemophilia A using recombinant Factor VIII gave rise to development of inhibitor antibodies to Factor VIII in 16 of 81 patients.
  • An immune tolerance may be obtained by removal of antibodies and treatment of patients with alloantibodies by high dosage regimen of Factor VIII, by low or intermediate dosage regimen or by combined treatment using cyclophosphamide and thereafter high doses of i.v. IgG.
  • WO 91/08773 it is disclosed that covalently bound conjugates of immunoglobulins and proteins such as an antigen may be used for inhibiting an immune response in a mammal to a protein such as Factor VIII.
  • a protein such as Factor VIII.
  • the present invention relates to a method of preventing or reducing the formation of Factor VIII inhibitory antibodies in a patient suffering from Haemophilia A and not previously treated with Factor VIII or only treated with a very limited amount of Factor VIII, the method comprising administration to the patient of a therapeutically effective amount of an immunoglobulin formulation before or during the initial treatments with Factor VIII.
  • immunoglobulin preparations primarily act through variable region-mediated mechanisms by providing the patient with regulatory elements of the normal immune system, thus providing physiological antibody-dependent control of autoreactivity (cf. L. Mouthon et al., Vox Sanp. 67, 1994, pp. 53-59).
  • the term "very limited amount of Factor VIII” is intended to refer to the situation where newborn children have been treated with Factor VIII substantially immediately after birth to stop bleeding incurred during birth, but have not subsequently been subjected to regular Factor VIII treatment.
  • the invention relates to the use of immunoglobulin for the preparation of a medicament for preventing or reducing the formation of Factor VIII inhibitory antibodies in a patient suffering from Haemophilia A and not previously treated with Factor VIII or treated with only a very small amount of Factor VIII.
  • the kit may also comprise measured amounts of a pharmaceutically acceptable vehicle, preferably sterile water for reconstituting the formulations.
  • a pharmaceutically acceptable vehicle preferably sterile water for reconstituting the formulations.
  • the Factor VIII to be used in accordance with the present invention may be Factor VIII isolated from plasma by methods known per se, e.g. as described in EP patent No. 83483, EP patent No. 150735 or EP patent No. 197901 or produced by recombinant techniques, e.g. as described in the patent applications listed below.
  • compositions comprising an immunoglobulin or a mixture of immuno ⁇ globulins may be any conventional immunoglobulin formulation in solution or in a lyophilized state comprising immunoglobulins and conventional additives and excipients such as saccharides or sugar alcohols, salts and stabilizers. Lyophilized formulations are reconstituted before administration, e.g. in sterile water.
  • the immunoglobulin may be given by subcutaneous or intramuscular injection or by intravenous infusion.
  • the dose of immunoglobulin may vary from about 0.1 to about 5 g per kg body weight per day.
  • a preferred dose regimen in accordance with the present invention is about 1 g/kg/day administered by i.v.
  • the immunoglobulin treatment may be repeated one or more times by administration of booster doses, for example after 18 and 24 weeks.
  • the immunoglobulin formulation may e.g. be the prep ⁇ aration commercially available from Novo Nordisk A/S, Bagsvaerd, Denmark under the trade mark Nordimmun ⁇ .
  • compositions comprising Factor VIII may be any conventional formulation in a lyophilized state comprising Factor VIII and conventional additives and excipients such as saccharides or sugar alcohols, salts and stabilizers for reconstitution before administration, e.g. using sterile water.
  • the therapeutic dose level of Factor VIII may vary from about 100 IU to about 2000 IU given by i.v. infusion being decided by the physician supervising the administration in accordance with the individual patient's need.
  • a prophylactic treatment may e.g. comprise giving from about 25 IU Factor VIII per kg bodyweight every other day up to about 200-300 IU Factor VIII per kg bodyweight per day.
  • a preferred does regimen is from 10 to 50 IU/kg body weight three times weekly, although higher or more frequent doses are sometimes appropriate, especially in the treatment of younger children.
  • the Factor VIII formulation may e.g. be the preparation commercially available from Novo Nordisk A/S, Bagsvaerd, Denmark under the Trade Mark Nordiocto* or Nordiate ® or preparations available from e.g. Miles Inc. or Baxter Biotech or Armour Pharmaceutical Company under the Trade Marks Kogenate ® or Recombinate* or Monoclate ® .
  • the invention is explained more in detail in the below Example which illustrates the invention. It is not to be considered as limiting the scope of the invention being defined by the appended claims.
  • Nordimmun* injection formulation from Novo Nordisk A/S
  • Plasma Product Unit contains human immunoglobulin G manufactured from plasma representing a donor pool per batch of more than 2,000 healthy, adult volunteers.
  • Nordimmun* 5 g i.v. injection formulation contains 5.0 g freeze-dried human immunoglobulin G.
  • the reconstituted product contains 4.6% human immunoglobulin G, 1.5% human albumin, 4.6% sucrose, and max 0.15 M sodium.
  • the Factor VIII preparation is an injection formulation containing Factor VIII purified directly from plasma.
  • the Factor VIII preparation has a high degree of purity and a specific activity > 100 IU/mg protein prior to formulation with albumin.
  • the preparation is virus-inactivated by two different methods, the so-called solvent-detergent (S/D) method and dry-heat treatment at 80°C for 72 hours.
  • the Factor VIII injection formulation is manufactured as 250 IU, 500 IU, and 1000 IU vials to be dissolved in sterile volume in a volume of 5 ml, 5 ml, and 10 ml, respectively.
  • a double blind study is set up to see whether inhibitor formation in patients may be prevented through preventive treatment combining Factor VIII and immunoglobulin therapy in the initial phase.
  • the trial includes patients who have previously had no more than 2 treatments with FVIII for their haemophilila A (PUPs).
  • the patient At inclusion in the study the patient is allocated a study number, and the patient initials as well as demographic data are written in the Case Record Forms. Before inclusion in the study a clinical examination of the patient will be carried out. The clinical examination will be repeated at the concluding control visit of the study.
  • Virological markers (HBsAg, anti-HBs IgG and IgM, Anti-HCV, anti HIV 1 + 2, and anti-Parvo B19 IgG and IgM. * IgG, IgA IgM.
  • the follow-up period starts after week 8.
  • Virological markers HBsAg, anti-HBs IgG and IgM, anti-HCV, anti-HIV 1 + 2, and anti-Parvo virus IgG and IgM are tested for in blood samples prior to start of the study and at regular intervals until the end of study.
  • Nordimmun ® infusion is given > 1 hour prior to the FVIII infusions.
  • Factor VIII therapy is on a three days a week prophylactic treatment regimen through the 6 months period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Méthode de prévention ou de réduction de la formation d'anticorps inhibant le facteur VIII chez un patient souffrant d'hémophilie A et n'ayant jamais été traité au facteur VIII ou ayant été préalablement traité avec une dose limitée de facteur VIII. Cette méthode consiste à administrer au patient une dose thérapeutiquement efficace d'une préparation à base d'immunoglobuline avant ou pendant les traitement initiaux au facteur VIII.
EP95927660A 1994-08-19 1995-08-15 Methode de traitement d'un patient a l'aide d'un compose biologiquement actif Withdrawn EP0776217A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK96294 1994-08-19
DK962/94 1994-08-19
PCT/DK1995/000330 WO1996005860A1 (fr) 1994-08-19 1995-08-15 Methode de traitement d'un patient a l'aide d'un compose biologiquement actif

Publications (1)

Publication Number Publication Date
EP0776217A1 true EP0776217A1 (fr) 1997-06-04

Family

ID=8099466

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95927660A Withdrawn EP0776217A1 (fr) 1994-08-19 1995-08-15 Methode de traitement d'un patient a l'aide d'un compose biologiquement actif

Country Status (4)

Country Link
EP (1) EP0776217A1 (fr)
JP (1) JPH10504310A (fr)
AU (1) AU3161695A (fr)
WO (1) WO1996005860A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19618851C1 (de) * 1996-05-10 1997-07-24 Octapharma Ag Verfahren zur Eignungsprüfung von Faktor VIII-haltigen Proteinfraktionen
ES2313783T3 (es) 1998-05-08 2009-03-01 Stichting Sanquin Bloedvoorziening Inhibidor para el diagnostico y el tratamiento de pacientes con hemofilia a.
SI20626A (sl) * 1998-09-21 2002-02-28 Genetics Institute, Inc. Postopki za zaviralno moduliranje imunskega odziva na terapevtske proteine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9605860A1 *

Also Published As

Publication number Publication date
WO1996005860A1 (fr) 1996-02-29
JPH10504310A (ja) 1998-04-28
AU3161695A (en) 1996-03-14

Similar Documents

Publication Publication Date Title
EP0719154B1 (fr) Facteur viii active utilise comme agent therapeutique et procede permettant de traiter une deficience en facteur viii
Edwards et al. Tri (n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives
AU651188B2 (en) Stabilized factor VIII preparations
Nilsson et al. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.
DiMichele et al. Hemophilia: a new approach to an old disease
Berntorp et al. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations
Knöbl et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb®)
Barandun et al. Clinical tolerance and catabolism of plasmin-treatedγ-globulin for intravenous application
HU214905B (hu) Eljárás VIII. faktor izolálására
JP2005511038A (ja) 第ｖｉｉｉ因子ｃ２ドメインのバリアント
US7049282B2 (en) Inhibition of complement action
WO1996005860A1 (fr) Methode de traitement d'un patient a l'aide d'un compose biologiquement actif
Morell Various immunoglobulin preparations for intravenous use
Nilsson et al. Induction of immune tolerance in hemophiliacs with inhibitors, by combined treatment with IVIG, cyclophosphamide and factor VIII or IX–the Malmö Model
EP0426913B1 (fr) Composition pharmaceutique et méthode pour la suppression de la production d'inhibiteur de facteur VIII
FI95440C (fi) Menetelmä plasmaperäisen C3b-inaktivaattoriliuoksen valmistamiseksi, joka ei sisällä oleellisesti tekijä B-aktiivisuutta eikä infektoivan viruksen aktiivisuutta
EP0609293A1 (fr) Traitement de l'hemophilie
US5543145A (en) Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
Zettervall et al. Characterisation of the tolerant state in a patient with haemophilia B after removal of high‐titre factor IX antibodies
JP2838166B2 (ja) 第▲ｖｉｉｉ▼因子阻害剤産生の抑制のための医薬組成物および方法
Scharrer et al. Products used to treat hemophilia: evolution of treatment for hemophilia A and B
Villarreal-Martínez et al. Efanesoctocog alfa. Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein, Treatment of hemophilia A
Arrighi et al. Factor VIII: c Concentrate Virus Inactivated: Progress in Purification by Using Classic Chromatographie Methods
Baumgartner et al. NORMAL IN VIVO KINETICS OF FACTOR VIII (F VIII) AND FACTOR IX (F IX) TREATED WITH TRI (N-BUIYL) PHOSPHATE (TNBP) AND TWEEN 80 FOR INACTIVATION OF VIRUSES
Larson The Clinical Development of Recombinant Coagulation Factor VIII (Kogenate®) for the Treatment of Hemophilia A

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19991130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000614